The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
And that could affect the drug's third-line accelerated approval.
A fresh licensing deal tidies up years of work between the two companies.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
